Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

AGM Statement

23 Oct 2008 14:25

RNS Number : 5547G
Marchpole Holdings PLC
23 October 2008
 



23 October 2008

Marchpole Holdings plc

("Marchpole" or "the Company")

Annual General Meeting Statement

At Marchpole Holdings Annual General Meeting held this morning the Chairman of Marchpole Holdings plc, Christopher Phillips, gave the following statement and update on current trading.

"At the time of the announcement on 5 August 2008 of our results for the 53 weeks ended 5 April 2008 we reported that the year to date had proved to be challenging, with very difficult trading conditions leading to a substantial loss for the full year. However, it has also been a year of significant change and some progress for the Group, as we continue to evolve into a diversified international luxury brand management business with a globally recognised portfolio of fashion brands.

Most recently we announced a successful fund raising of £2.5 million with Atlas Design, which provides the Company with a more secure foundation from which to pursue growth opportunities as they arise. In addition we have also appointed Atlas Chairman Peter Wahlberg and Atlas CEO Allan Ladow to the Board of Marchpole as non-executive directors, and we look forward to benefiting from the additional experience that they bring to the Company.

Significantly during the current financial period we have entered into a joint venture and licensing agreement with the DKNY menswear label, under the terms of which Marchpole will source, design, produce and distribute a full range of DKNY menswear apparel throughout the world, excluding the Indian and Japanese markets. The agreement is for an initial period of seven years, with the option to extend the licence for a further seven years.

Trading conditions in the current financial year continue to be extremely difficult as a result of the deterioration in consumer markets, following the ongoing global financial crisis. 

The Board is taking all appropriate measures to deal with the current challenging economic environment and is maintaining a regular dialogue with the Company's bankers, in common with most other businesses exposed to the retail sector. In the current environment the directors continue to review all options and will provide an update on the trading performance with the interim statement in early December."

For further information please contact:

For further information, please contact :

Bell Pottinger Corporate & Financial 020 7861 3232

David Rydell / Emma Kent

Marchpole Holdings plc 020 7908 7777

Chris Phillips, Chairman

Michael MorrisExecutive Deputy Chairman 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMUOUORWRRRUAA
Date   Source Headline
4th May 20177:00 amRNSInitiation of BPS-804 Phase 2b study
28th Apr 20173:37 pmRNSHolding(s) in Company
28th Apr 201712:53 pmRNSHolding(s) in Company
28th Apr 201710:05 amRNSHolding(s) in Company
26th Apr 20177:00 amRNSConversion of loan note and issue of equity
24th Apr 20176:07 pmRNSHolding(s) in Company
5th Apr 20177:00 amRNSGrant of Options and Awards
3rd Apr 20177:00 amRNSResults of Placing
31st Mar 20175:54 pmRNSResults of Placing
29th Mar 201712:30 pmRNSProposed Placing
15th Mar 20177:00 amRNSPosting of Annual Report and Notice of AGM
7th Mar 20177:00 amRNSPositive recommendation for BGS-649 Phase 2b trial
27th Feb 20177:00 amRNSPreliminary Results
20th Feb 20177:00 amRNSEMA Adaptive Pathways programme accepts BPS-804
23rd Jan 20177:05 amRNSPresentation at Shares Spotlight Evening
23rd Jan 20177:00 amRNSThree abstracts accepted for ATS Meeting
12th Jan 20177:01 amRNSDirectorate update
5th Jan 201712:00 pmRNSMereo BioPharma to Present at Biotech Showcase
12th Dec 20167:00 amRNSBusiness Update
7th Nov 20167:10 amRNSAppointment of Chief Financial Officer
3rd Nov 20167:00 amRNSPositive Phase 1 interaction study with BCT-197
5th Oct 20167:00 amRNSDirectorate Change
16th Sep 20167:00 amRNSHalf-year Report
9th Aug 20164:04 pmRNSNotice of Results
18th Jul 20161:25 pmRNSResult of AGM
30th Jun 20167:00 amRNSBPS-804 granted EU orphan drug status
24th Jun 201612:47 pmRNSNotice of AGM
9th Jun 20161:17 pmRNSDirector/PDMR Shareholding
9th Jun 20168:01 amRNSFirst Day of Dealings on AIM
10th Nov 20086:21 pmRNSFurther re financial position
4th Nov 20083:01 pmRNSStatement re suspension
4th Nov 20083:00 pmRNSSuspension
23rd Oct 20084:35 pmRNSHolding(s) in Company
23rd Oct 20082:25 pmRNSAGM Statement
2nd Oct 20083:14 pmRNSHolding(s) in Company
23rd Sep 200810:02 amRNSNotice of AGM
1st Sep 200810:06 amRNSHolding(s) in Company
29th Aug 20083:20 pmRNSResult of GM and Interim Mana
26th Aug 200810:13 amRNSHolding(s) in Company
19th Aug 20082:22 pmRNSHolding(s) in Company
14th Aug 20084:23 pmRNSHolding(s) in Company
13th Aug 200811:00 amRNSDirectorate Change
8th Aug 200811:14 amRNSHolding(s) in Company
8th Aug 200811:03 amRNSHolding(s) in Company
7th Aug 20084:46 pmRNSHolding(s) in Company
6th Aug 20084:41 pmRNSSecond Price Monitoring Extn
6th Aug 20084:36 pmRNSPrice Monitoring Extension
6th Aug 20083:17 pmRNSDirector/PDMR Shareholding
6th Aug 20087:08 amRNSFundraising and New Board App
6th Aug 20087:05 amRNSNew Joint Venture

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.